Zhejiang Wenda Pharmaceutical has just earned a Breakthrough Therapy Designation from China’s drug regulator for its experimental oral medicine NHWD‑870 HCI. The drug is a BET‑inhibitor designed to target advanced mid‑line NUT carcinoma—a rare, fast‑growing cancer that typically strikes young adults and carries a median survival of only about 6½ months. Because NUT carcinoma is often misdiagnosed, most patients are already in late stages when treatment begins, and no approved targeted therapies exist worldwide. In a Phase II trial that wrapped up in December 2025, 40 patients with advanced disease received NHWD‑870. The results were striking: among 20 participants with chest‑based tumors, 45 % saw their tumors shrink (objective response rate). Overall, the median overall survival for all participants rose to 9.3 months—well beyond the typical outcome with standard chemotherapy. Early safety data also suggest the drug is well tolerated. If these findings hold up in later studies, NHWD‑870 could become the first effective, oral, targeted treatment for NUT carcinoma, extending lives and improving quality of life for patients who currently have few options.
Read moreA wave of new research is reshaping how we think about depression treatment. Scientists at Hubei University of Chinese Medicine showed that the traditional formula Ganmai Dazao Tang can calm depressive‑like behavior in stressed mice by balancing gut microbes, tweaking brain chemistry, and easing inflammation – a modern glimpse into the ancient “gut‑brain” connection. In a parallel study, electroacupuncture was found to protect brain support cells (astrocytes) from shrinking, offering a drug‑free option for major depressive disorder. Meanwhile, clinicians have issued clear guidelines for light therapy: a 10,000‑lux white light session each morning for 30 minutes can reset circadian rhythms and lift mood in both seasonal and non‑seasonal depression. A team in Shandong uncovered that a centuries‑old herbal blend, when mixed in a precise 9:1 ratio of two key compounds, can dampen the brain’s inflammatory storm, providing the first biological proof of traditional Chinese medicine’s “king‑minister‑assistant‑envoy” theory. Researchers at Southern Medical University discovered that friendly gut bacteria boost creatine transport to the brain, improving energy metabolism and easing depressive symptoms. On the precision‑medicine front, testing for the CYP2C19 gene helps predict how well patients will respond to sertraline, while a large dietary analysis suggests that higher animal‑protein intake may lower depression risk, especially for women and seniors. Together, these findings point to a future where ancient wisdom, lifestyle tweaks, and personalized medicine join forces against depression.
Read moreAt the recent BIONNOVA Biopharma Innovators Forum in Shanghai, Taimei Zhiyan Pharmaceuticals highlighted a fresh approach to early‑stage drug testing that could reshape China’s role in the global pharma arena. Dr. Zhang Zibao, the company’s co‑founder and COO, explained that China is no longer just a regional market; it’s becoming a two‑way clinical hub where domestic innovators send their discoveries abroad while foreign firms set up first‑in‑human (FIH) studies here. The market is booming – analysts predict a 12‑16% annual growth in China’s early‑phase sector through 2028, outpacing the global average of 7‑9%. This surge is driven by three hard advantages: a large pool of patients, fast regulatory approvals, and high‑quality research talent. Yet the rapid expansion brings challenges: limited experience with FIH trials, higher risk as proof‑of‑concept failures move earlier, and costly, fragmented development models. Taimei Zhiyan proposes a hybrid platform that blends the control of in‑house teams with the cost‑efficiency of local CROs and the compliance strength of global CROs. By integrating these resources, the model aims to deliver faster, cheaper, and higher‑quality data for both Chinese and international drug developers, helping them navigate the complex early‑phase landscape while keeping pace with the industry’s accelerating growth.
Read more